

# Read & Publish Open Access initiative



## Development



Development, launched in 1953, is a leading primary research journal in the field of developmental biology. The journal publishes cutting-edge articles and reviews across the spectrum of plant and animal development.

Topic coverage ranges from stem cells and nuclear reprogramming to evolutionary developmental and systems biology, from neurobiology to regional specification, morphogenesis and organogenesis, and from epigenetics to the aetiology of disease.

In addition to primary research articles, Development publishes a range of commissioned review-based articles. These synthesise the latest advances in the field, put forward new hypotheses to provoke debate and inspire new research directions, and inform newcomers to the field.

Development was designated as one of the 100 most influential journals of the past 100 years by the SLA BioMedical & Life Sciences Division in 2009.

### Readership

Development is read by scientists at all levels and from a broad field of expertise – including plant and animal biologists, geneticists, molecular biologists, cell biologists, paediatricians, neurologists, embryologists and stem cell scientists.

### Abstracting and indexing services

Development is abstracted and/or indexed (amongst others) by: BIOBASE, CAB abstracts, Cambridge Scientific Abstracts, Current Contents, EMBASE, ISI Web of Science, Medline and Scopus.

### Open Access commitment

The Company of Biologists has a long-standing commitment to Open Access, and our hybrid journals (including Development) were the first in the world to be awarded Transformative Journal status by Plan S. All our journals (including our fully Open Access journals – Disease Models & Mechanisms and Biology Open) are included in our Read & Publish Open Access agreements.

### Key metrics

- 2022 Impact Factor: 4.6
- Five-year Impact Factor: 6.1
- Two-year citation median: 3.0
- Eigenfactor score: 0.04317
- Article Influence Score: 2.478
- Immediacy Index: 1.1
- h-index: 349
- Scopus: 8.7
- SJR indicator: 2.472
- SNIP: 1.291



# Development

Available through The Company of Biologists'  
Read & Publish Open Access initiative

## Expert team of academic editors

### Editor-in-Chief

- James Briscoe (Francis Crick Institute, UK)

### Deputy Editor

- Steve Wilson (University College London, UK)

### Editors

- Swathi Arur (MD Anderson Cancer Center, USA)
- Benoit Bruneau (Gladstone Institutes, USA)
- Cassandra Extavour (Harvard University, USA)
- François Guillemot (Francis Crick Institute, UK)
- Anna-Katerina Hadjantonakis (Memorial Sloan Kettering Cancer Center, USA)
- Haruhiko Koseki (RIKEN Centre for Allergy and Immunology, Japan)
- Thomas Lecuit (Marseille University, France)
- Liz Robertson (University of Oxford, UK)
- Peter Rugg-Gunn (Babraham Institute, UK)
- Debra Silver (Duke University, USA)
- James Wells (Cincinnati Children's Hospital Medical Center, USA)

### Associate Editors

- Paul François (McGill University, Canada)
- Matthias Lutolf (École Polytechnique Fédérale de Lausanne, Switzerland)
- Irene Miguel-Aliaga (Imperial College London and MRC-LMS, UK)
- Hanna Mikkola (University of California, Los Angeles, USA)
- Samantha Morris (Washington University in St Louis, USA)
- Ken Poss (Duke University, USA)

## What are the benefits of Read & Publish agreements?

- Uncapped fee-free Open Access publishing of research articles in all our journals: Development, Journal of Cell Science, Journal of Experimental Biology, Disease Models & Mechanisms and Biology Open
- Unlimited "read" access to our three hybrid journals (Development, Journal of Cell Science and Journal of Experimental Biology) and their archives
- Transparent cost-neutral pricing
- Single annual fee covers reading and publishing
- Easy to switch from a subscription to a Read & Publish agreement
- Compliant with funder mandates including Plan S



“The Read & Publish agreement between The Company of Biologists and the University of Cambridge made my life so easy. I could send my manuscript to Development knowing that, if accepted, publishing in my favourite journal would be straightforward, comply with my funder's requirements and be free at point of use. All that plus a free tree in The Forest of Biologists!”

**Dr Emma Rawlins**, Gurdon Institute, University of Cambridge, UK

## Benefits of Open Access publishing



Usage increase **>3x**




Citation advantage **1.1-1.4x**



Altmetrics boost **1.2-1.9x**

Figures based on the latest available data from Impact Vizor and Altmetric Explorer

## Read & Publish: number of participating institutions




**biologists.com/read-publish**



# Read & Publish Open Access initiative



## Journal of Cell Science



Launched in 1853, Journal of Cell Science publishes cutting-edge articles and reviews encompassing all aspects of cell biology – from the inner workings of individual cells to how they react and respond to each other and their environment.

Topics covered range from cell signalling, cell migration, cell adhesion, cell division and cell polarity, through to cancer cell biology, immunology, biochemistry and mechanobiology.

In addition to primary research articles, Journal of Cell Science publishes a range of commissioned review-based articles. These articles synthesise the latest advances in the field, put forward new hypotheses to provoke debate and inspire new research directions, and inform newcomers to the field.

### Readership

Journal of Cell Science is read by a broad spectrum of scientists at all levels, including cell biologists, developmental biologists, molecular biologists, plant biologists and neuroscientists.

### Abstracting and indexing services

Journal of Cell Science is abstracted and/or indexed by (amongst others): BIOBASE, CAB abstracts, Cambridge Scientific Abstracts, Current Contents, EMBASE, Clarivate Analytics Web of Science, Medline and Scopus.

### Open Access commitment

The Company of Biologists has a long-standing commitment to Open Access, and our hybrid journals (including Journal of Cell Science) were the first in the world to be awarded Transformative Journal status by Plan S. All our journals (including our fully Open Access journals – Disease Models & Mechanisms and Biology Open) are included in our Read & Publish Open Access agreements.

### Key metrics

- 2022 Impact Factor: 4.0
- Five-year Impact Factor: 4.6
- Two-year citation median: 3.0
- Eigenfactor score: 0.02796
- Article Influence Score: 1.699
- Immediacy Index: 1.5
- h-index: 298
- Scopus: 7.8
- SJR indicator: 1.842
- SNIP: 0.990





## Expert team of academic editors

### Editor-in-Chief

- Michael Way (The Francis Crick Institute, UK)

### Deputy Editor-in-Chief

- Kathleen J. Green (Northwestern University Medical School, USA)

### Editors

- Renata Basto (Institut Curie, France)
- Daniel Billadeau (Mayo Clinic, USA)
- Simon Cook (Babraham Institute, UK)
- Andrew Ewald (Johns Hopkins School of Medicine, USA)
- Caroline Hill (The Francis Crick Institute, UK)
- Kairbaan Hodivala-Dilke (Barts Cancer Institute, UK)
- Megan King (Yale University, USA)
- Jennifer Lippincott-Schwartz (Janelia Research Campus, USA)
- Guangshuo Ou (Tsinghua University, China)
- Rob Parton (University of Queensland, Australia)
- Giampietro Schiavo (University College London, UK)
- Richa Rikhy (IISER, Pune, India)
- Tamotsu Yoshimori (Osaka University, Japan)

## What are the benefits of Read & Publish agreements?

- Uncapped fee-free Open Access publishing of research articles in all our journals: Development, Journal of Cell Science, Journal of Experimental Biology, Disease Models & Mechanisms and Biology Open
- Unlimited "read" access to our three hybrid journals (Development, Journal of Cell Science and Journal of Experimental Biology) and their archives
- Transparent cost-neutral pricing
- Single annual fee covers reading and publishing
- Easy to switch from a subscription to a Read & Publish agreement
- Compliant with funder mandates including Plan S



“ We are delighted to publish our article in Journal of Cell Science. The manuscript was handled professionally throughout and the whole process was straightforward. I am particularly happy the University of Manchester has a Read & Publish agreement with The Company of Biologists which made the Open Access publication of the accepted version rapid and painless. I would thoroughly recommend JCS to other investigators in the field.”

**Professor Martin Lowe**, University of Manchester, UK

## Benefits of Open Access publishing



Usage increase **>3x**




Citation advantage **1.1-1.4x**



Altmetrics boost **1.2-1.9x**

## Read & Publish: number of participating institutions



Figures based on the latest available data from Impact Vizor and Altmetric Explorer





# Read & Publish Open Access initiative



## Journal of Experimental Biology



Launched in 1923, Journal of Experimental Biology is the leading primary research journal in comparative animal physiology and biomechanics. It publishes papers on the form and function of living organisms at all levels of biological organisation, from the molecular and subcellular to the integrated whole animal.

Topic coverage ranges from biochemical physiology to biomechanics, from cardiovascular and respiratory physiology to conservation physiology, from endocrinology to ecological and evolutionary physiology, and from neurobiology to neuroethology and sensory physiology.

In addition to primary research articles, Journal of Experimental Biology publishes a range of commissioned review-based articles. These synthesise the latest advances in the field, put forward new hypotheses to provoke debate and inspire new research directions, and inform newcomers to the field.

### Readership

Journal of Experimental Biology is read by an interdisciplinary group of scientists who study comparative biomechanics and molecular, cellular and organismal physiology in an evolutionary and environmental context including systemic, cellular and molecular physiologists, neuroscientists, ecophysiologists, biomechanists and biochemists.

### Abstracting and indexing services

Journal of Experimental Biology is abstracted and/or indexed by (amongst others): BIOBASE, CAB abstracts, Cambridge Scientific Abstracts, Current Contents, EMBASE, Clarivate Analytics Web of Science, Medline and Scopus.

### Open Access commitment

The Company of Biologists has a long-standing commitment to Open Access, and our hybrid journals (including Journal of Experimental Biology) were the first in the world to be awarded Transformative Journal status by Plan S. All our journals (including our fully Open Access journals – Disease Models & Mechanisms and Biology Open) are included in our Read & Publish Open Access agreements.

### Key metrics

- 2022 Impact Factor: 2.8
- Five-year Impact Factor: 3.2
- Two-year citation median: 2.0
- Eigenfactor score: 0.01933
- Article influence score: 0.893
- Cited half-life: 12.8
- Immediacy Index: 1.0
- h-index: 203
- Scopus: 5.5
- SJR indicator: 1.018
- SNIP: 0.957





## Expert team of academic editors

### Editor-in-Chief

- Craig E. Franklin (The University of Queensland, Australia)

### Deputy Editors-in-Chief

- Sheila N. Patek (Duke University, USA)
- Patricia A. Wright (University of Guelph, Canada)

### Monitoring Editors

- Monica A. Daley (University of California, Irvine, USA)
- Stuart Egginton (University of Leeds, UK)
- Kathleen M. Gilmour (University of Ottawa, Canada)
- Almut Kelber (Lund University, Sweden)
- Matthew J. McHenry (University of California, Irvine, USA)
- Sanjay P. Sane (National Center for Biological Sciences, India)
- Patricia M. Schulte (The University of British Columbia, Canada)
- John S. Terblanche (Stellenbosch University, South Africa)

## What are the benefits of Read & Publish agreements?

- Uncapped fee-free Open Access publishing of research articles in all our journals: Development, Journal of Cell Science, Journal of Experimental Biology, Disease Models & Mechanisms and Biology Open
- Unlimited "read" access to our three hybrid journals (Development, Journal of Cell Science and Journal of Experimental Biology) and their archives
- Transparent cost-neutral pricing
- Single annual fee covers reading and publishing
- Easy to switch from a subscription to a Read & Publish agreement
- Compliant with funder mandates including Plan S



“ I think the Read & Publish agreement is a great and important step towards making research more open and available to everyone, which is something I think is vital. For many early-career scientists like myself, the funding to publish Open Access is not always there. Being given the opportunity to do so, whilst publishing in journals that are well renowned in the field, will make sure that work such as ours is immediately available to all interested parties. ”

**Merijn Driessen**, University of Groningen, Netherlands

## Benefits of Open Access publishing



Usage increase **>3x**




Citation advantage **1.1-1.4x**



Altmetrics boost **1.2-1.9x**

## Read & Publish: number of participating institutions




Figures based on the latest available data from Impact Vizor and Altmetric Explorer



# Read & Publish Open Access initiative



## Disease Models & Mechanisms



Launched in 2008, Disease Models & Mechanisms is an Open Access biomedical research journal that advances understanding of the mechanism, diagnosis and therapy of human disease.



Interdisciplinary in scope, Disease Models & Mechanisms covers a diverse range of diseases, including cancer, infectious diseases, developmental disorders, musculoskeletal disorders, and neurodegenerative and neurological diseases. Published research utilizes *in vitro* or *ex vivo* models, such as stem-cell-based models, organoids, patient material, model organisms, microorganisms, viruses and computational approaches.

In addition to research articles, Disease Models & Mechanisms features expert reviews, perspectives and interviews with leading scientists to address current and emerging themes in biomedical science.

### Readership

Disease Models & Mechanisms aspires to connect and support all those working at every level of disease research, from basic researchers to clinicians at the forefront of patient care. Content is freely available to the journal's communities of basic and clinical researchers, those working for pharmaceutical companies, health professionals, patients and their advocates and families.

### Abstracting and indexing services

Disease Models & Mechanisms is abstracted and/or indexed by (amongst others): BIOBASE, CAB abstracts, Cambridge Scientific Abstracts, Current Contents, EMBASE, Clarivate Analytics Web of Science, Medline, Scopus and the Directory of Open Access Journals (DOAJ).

### Open Access commitment

DMM has been awarded the Directory of Open Access Journals seal – given to journals that achieve a high level of openness, adhere to best practice and have high publishing standards. The Company of Biologists has a long-standing commitment to Open Access, and our hybrid journals were the first in the world to be awarded Transformative Journal status by Plan S. All our journals are included in our Read & Publish Open Access agreements.

### Key metrics

- 2022 Impact Factor: 4.3
- Five-year Impact Factor: 5.1
- Two-year citation median: 3.0
- Eigenfactor score: 0.00806
- Article Influence Score: 1.73589
- Immediacy Index: 1.4
- h-index: 99
- Scopus: 7.5
- SJR indicator: 1.489
- SNIP: 0.979



# Disease Models & Mechanisms

Available through The Company of Biologists' Read & Publish Open Access initiative

## Expert team of academic editors

### Editor-in-Chief

- E. Elizabeth Patton (MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, UK)

### Deputy Editor-in-Chief

- Elaine R. Mardis (Nationwide Children's Hospital, Ohio, USA)

### Editors

- James Amatruda (Children's Hospital Los Angeles, CA, USA)
- Steven J. Clapcote (University of Leeds, UK)
- Tatsushi Igaki (Kyoto University, Japan)
- Monica J. Justice (The Hospital for Sick Children [SickKids], Toronto, Canada)
- Vivian Li (The Francis Crick Institute, London, UK)
- Karen Liu (King's College London, UK)
- Owen Sansom (Beatson Institute for Cancer Research, Glasgow, UK)
- David M. Tobin (Duke University School of Medicine, Durham, NC, USA)

### Associate Editors

- Sally Dunwoodie (Victor Chang Cardiac Research Institute, Australia)
- Monkol Lek (Yale School of Medicine, USA)
- Sumana Sanyal (University of Oxford, UK)
- Ian Smyth (Monash University, Australia)
- Eckhard Wolf (Gene Center, LMU Munich, Germany)

## What are the benefits of Read & Publish agreements?

- Uncapped fee-free Open Access publishing of research articles in all our journals: Development, Journal of Cell Science, Journal of Experimental Biology, Disease Models & Mechanisms and Biology Open
- Unlimited "read" access to our three hybrid journals (Development, Journal of Cell Science and Journal of Experimental Biology) and their archives
- Transparent cost-neutral pricing
- Single annual fee covers reading and publishing
- Easy to switch from a subscription to a Read & Publish agreement
- Compliant with funder mandates including Plan S



“DMM is well respected in my field and I was delighted to publish our research here. Alongside being a publisher, The Company of Biologists do a stellar job in their support of the scientific community. The Read & Publish agreement with University of Sheffield makes it even more attractive to publish in this collection of journals, allowing immediate Open Access for all.”

Dr Phil Elks, University of Sheffield, UK

## Benefits of Open Access publishing



Usage increase **>3x**




Citation advantage **1.1-1.4x**



Altmetrics boost **1.2-1.9x**

Figures based on the latest available data from Impact Vizor and Altmetric Explorer

## Read & Publish: number of participating institutions



**biologists.com/read-publish**






# Read & Publish Open Access initiative



## Biology Open



Biology Open was launched in 2012 as the first fully Open Access journal published by The Company of Biologists. It publishes rigorously conducted research that spans the breadth of the biological and biomedical sciences.



From adenovirus to zebrafish, via cancer biology and stem cells, the Biology Open team is committed to Open Access publishing as a mechanism to widen access, promote equality and ensure sustainability in publishing in the biological sciences.

Biology Open aims to support early-career researchers in particular. It publishes **First Person interviews** with the first authors of research papers, and creates career development opportunities through its early-career researcher focused **Meeting Reviews** and **Future Leader Reviews** initiative.

### Readership

Biology Open is read by scientists at all career levels and from a broad field of expertise – including plant and animal biologists, geneticists, molecular biologists, cell biologists, and stem cell and developmental biologists, as well as scientists who study molecular, cellular and organismal physiology. Content is freely available to the journal's communities of researchers and the general public.

### Abstracting and indexing services

Biology Open is abstracted and/or indexed by (amongst others): Biological Abstracts, BIOSIS, CAB abstracts, Chemical Abstracts, Clarivate Analytics Web of Science, Medline, PMC, PubMed, Scopus and the Directory of Open Access Journals (DOAJ).

### Open Access commitment

BiO was the first fully Open Access journal launched by The Company of Biologists. It has been awarded the Directory of Open Access Journals seal – given to journals that achieve a high level of openness, adhere to best practice and high publishing standards. The Company has a long-standing commitment to Open Access, and our hybrid journals were the first in the world to be awarded Transformative Journal status by Plan S. All our journals are included in our Read & Publish Open Access agreements.

### Key metrics

- 2022 Impact Factor: 2.4
- Five-year Impact Factor: 2.3
- Two-year citation median: 2.0
- Eigenfactor score: 0.00554
- Article Influence Score: 0.681
- Immediacy Index: 0.6
- h-index: 52
- Scopus: 4.7
- SJR indicator: 0.824
- SNIP: 0.657





## Expert team of academic editors

### Editor-in-Chief

- Daniel Gorelick (Baylor College of Medicine, Houston, USA)

### Deputy Editors

- Catherine L. Jackson (Institut Jacques Monod, Paris, France)
- Tristan Rodríguez (Imperial College London, UK)

### Editors

- Alissa Armstrong (University of South Carolina, USA)
- Kendra J. Greenlee (North Dakota State University, USA)
- Lewis Halsey (University of Roehampton, London, UK)
- Christopher A. Maher (Washington University School of Medicine, USA)
- Lauren Nadler (The University of Southampton, UK)
- Luca Scorrano (University of Padua, Italy)

## What are the benefits of Read & Publish agreements?

- Uncapped fee-free Open Access publishing of research articles in all our journals: Development, Journal of Cell Science, Journal of Experimental Biology, Disease Models & Mechanisms and Biology Open
- Unlimited "read" access to our three hybrid journals (Development, Journal of Cell Science and Journal of Experimental Biology) and their archives
- Transparent cost-neutral pricing
- Single annual fee covers reading and publishing
- Easy to switch from a subscription to a Read & Publish agreement
- Compliant with funder mandates including Plan S



“Well done to The Company of Biologists for their excellent Read & Publish deals, including with my institution, St George's, University of London. It's a great pleasure and benefit for our paper in Biology Open to be immediately available to all, free of charge.”

**Professor Dorothy C. Bennett**, St. George's, University of London, UK

## Benefits of Open Access publishing



Usage increase **>3x**



Citation advantage **1.1-1.4x**



Altmetrics boost **1.2-1.9x**

Figures based on the latest available data from Impact Vizor and Altmetric Explorer

## Read & Publish: number of participating institutions

